2-Hydroxybenzylamine

2-羟基苄胺

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug Name2-Hydroxybenzylamine
Drug Alias Name邻氨甲基苯酚邻羟基苄胺2-HOBA
ClassificationSmall molecules > Heterocyclic drugsNatural product/Extract > Plants extract
Mechanisms of ActionAnti-oxidative stressFree radicals scavengers
TargetsFree radicals
Therapy Area/IndicationsCognitive DysfunctionInflammationLupus Erythematosus, Systemic +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVanderbilt University Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesMTI Biotech IncVanderbilt University Medical Center
Inactive CompaniesN/A
Active IndicationsCognitive DysfunctionInflammationLupus Erythematosus, Systemic +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A